Latest in Head, Neck & Thyroid Cancers

Head, Neck & Thyroid Cancers at a glance

The 10 latest articles on Head, Neck & Thyroid Cancers come from 9 sources, published between Oct 8 and Nov 9. Most come from newswise.com (2).

People in these stories: Rybrevant Faspro (3), Amanda Hollinger (2)

Organizations: FDA (6), EGFR (5), Johnson & Johnson (4), J&J (2), Neck Cancer Alliance (2), UCLA (2)

Places: U.S. (3), MARIPOSA (2), LAZCLUZE (2), CHRYSALIS (2), PE (2)

ajmc.com
307 words

FDA Approves First Dual-Targeted Therapy for Advanced HNSCC

The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer. The FDA granted accelerated approval on November 5 to amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; Johnson & Johnson) for adults with recurrent or metastatic…

medscape.com
753 words

De-escalation of Surgery Safe for Low-Risk Thyroid Cancer

PHILADELPHIA — Patients with low-risk differentiated thyroid cancer treated with the less invasive approach of thyroid lobectomy vs total thyroidectomy, as recommended in American Thyroid Association (ATA) de-escalation guidelines from 2015, show no significant increases in the risk for disease recurrence, new…

finance.yahoo.com
1,607 words

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study Data highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth…

wvgazettemail.com
1,603 words

Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

Today's approval follows the FDA Breakthrough Therapy Designation (BTD) granted in February 2026 and Priority Review designation in July 2026. This indication was granted accelerated approval based on clinically meaningful and durable tumor response demonstrated in the Phase 1b/2 OrigAMI-4 trial.1 Continued approval…

Head, Neck & Thyroid Cancers

Mouth, throat and other head and neck cancers, including those linked to HPV, and thyroid cancer.

  • 19 Tracked terms
  • Last 30 days Feed window

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.